» Articles » PMID: 31542363

Exosomal MiRNAs in Central Nervous System Diseases: Biomarkers, Pathological Mediators, Protective Factors and Therapeutic Agents

Overview
Journal Prog Neurobiol
Specialty Neurology
Date 2019 Sep 23
PMID 31542363
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomes are small bilipid layer-enclosed extracellular vesicles that can be found in tissues and biological fluids. As a key cell-to-cell and distant communication mediator, exosomes are involved in various central nervous system (CNS) diseases, potentially through transferring their contents such as proteins, lipids and nucleic acids to the target cells. Exosomal miRNAs, which are small non-coding RNAs in the exosomes, are known to be more stable than free miRNAs and therefore have lasting effects on disease-related gene expressions. There are distinct profiles of exosomal miRNAs in different types of CNS diseases even before the onset of irreversible neurological damages, indicating that exosomal miRNAs within tissues and biological fluids could serve as promising biomarkers. Emerging evidence has also demonstrated the pathological effects of several exosomal miRNAs in CNS diseases via specific modulation of disease-related factors. Moreover, exosomes carry therapeutically beneficial miRNAs across the blood-brain-barrier, which can be exploited as a powerful drug delivery tool to help alleviating multiple CNS diseases. In this review, we summarize the recent progress made in understanding the biological roles of exosomal miRNAs as potential diagnostic biomarkers, pathological regulators, and therapeutic targets/drugs for CNS diseases. A comprehensive discussion of the main concerns and challenges for the applications of exosomal miRNAs in the clinical setting is also provided.

Citing Articles

Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges.

Almasi F, Abbasloo F, Soltani N, Dehbozorgi M, Moghadam Fard A, Kiani A Mol Neurobiol. 2025; .

PMID: 39998798 DOI: 10.1007/s12035-025-04788-7.


Roles, Functions, and Pathological Implications of Exosomes in the Central Nervous System.

Spinelli S, Tripodi D, Corti N, Zocchi E, Bruschi M, Leoni V Int J Mol Sci. 2025; 26(3).

PMID: 39941112 PMC: 11818369. DOI: 10.3390/ijms26031345.


Stem cell-derived exosome delivery systems for treating atherosclerosis: The new frontier of stem cell therapy.

Tariq H, Bukhari S, An R, Dong J, Ihsan A, Younis M Mater Today Bio. 2025; 30:101440.

PMID: 39866781 PMC: 11758955. DOI: 10.1016/j.mtbio.2024.101440.


Exosome: an overview on enhanced biogenesis by small molecules.

Bavafa A, Izadpanahi M, Hosseini E, Hajinejad M, Abedi M, Forouzanfar F Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39862264 DOI: 10.1007/s00210-024-03762-9.


Exosomes: new targets for understanding axon guidance in the developing central nervous system.

Liu M, Teng T Front Cell Dev Biol. 2025; 12():1510862.

PMID: 39850798 PMC: 11754257. DOI: 10.3389/fcell.2024.1510862.


References
1.
Kumar S, Reddy P . Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?. Biochim Biophys Acta. 2016; 1862(9):1617-27. PMC: 5343750. DOI: 10.1016/j.bbadis.2016.06.001. View

2.
Miranda K, Bond D, McKee M, Skog J, Paunescu T, da Silva N . Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010; 78(2):191-9. PMC: 4451567. DOI: 10.1038/ki.2010.106. View

3.
Vinish M, Anand A, Prabhakar S . Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta Biochim Pol. 2011; 58(2):165-9. View

4.
Montecalvo A, Larregina A, Shufesky W, Stolz D, Sullivan M, Karlsson J . Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2011; 119(3):756-66. PMC: 3265200. DOI: 10.1182/blood-2011-02-338004. View

5.
Kuss A, Chen W . MicroRNAs in brain function and disease. Curr Neurol Neurosci Rep. 2008; 8(3):190-7. DOI: 10.1007/s11910-008-0031-0. View